Skip nav

23rd February 2012. Norwegian oncology biopharma company BerGenBio AS has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic. The lead investors in the raise were Sarsia Seed AS and Investinor AS.

Bridgehead International was appointed by Investinor AS, the Government of Norway venture capital investment corporation, to carry out a due diligence study on BerGenBio AS. This covered the main technical and commercial elements of the company’s programmes, its business plans and the capacity of the management team to deliver.

Bridgehead’s CEO, Timothy Fitzgerald, commented: ‘Bridgehead’s expert team was able to provide a rapid, in depth assessment of the BerGenBio portfolio, and to assess this leading edge science in a clear commercial context. It is very satisfying to see that our advisory work has contributed to this investment...

Read full release